Patents Issued in July 9, 2020
-
Publication number: 20200216839Abstract: Contiguity information is important to achieving high-quality de novo assembly of mammalian genomes and the haplotype-resolved resequencing of human genomes. The methods described herein pursue cost-effective, massively parallel capture of contiguity information at different scales.Type: ApplicationFiled: October 28, 2019Publication date: July 9, 2020Applicant: University of Washington Through Its Center for CommercializationInventors: Jay Ashok Shendure, Jerrod Joseph Schwartz, Andrew Colin Adey, Cho li Lee, Joseph Brian Hiatt, Jacob Otto Kitzman, Akash Kumar
-
Publication number: 20200216840Abstract: The present disclosure generally relates to sequencing two or more genes expressed in a single cell in a high-throughput manner using reverse transcriptases. More particularly, the present disclosure relates to a method for high-throughput sequencing of pairs of transcripts co-expressed in single cells (e.g., antibody VH and VL coding sequence) to determine pairs of polypeptide chains that comprise immune receptors.Type: ApplicationFiled: July 27, 2018Publication date: July 9, 2020Inventors: Hidetaka TANNO, George GEORGIOU, Jonathan MCDANIEL, Gregory IPPOLITO, Andrew ELLINGTON
-
Publication number: 20200216841Abstract: Provided herein are compositions and methods to assess the genomic landscape of fixed cells using light activated oligonucleotides that can be directed to the nucleus, mitochondria, or cytoplasm of fixed cells and that, upon activation, can be extended for in situ copying of nuclear single-stranded DNA (i.e., open chromatin), open mitochondrial DNA, and/or cytoplasmic RNA into barcoded complementary DNA. These methods also provide for gene specific 3D chromatin structural niche analysis.Type: ApplicationFiled: January 7, 2020Publication date: July 9, 2020Applicants: Agilent Technologies, Inc., The Trustees of the University of PennsylvaniaInventors: James EBERWINE, Jae-Hee LEE, Jifen LI, Stephen FISHER, Youtao LU, Junhyong KIM, Jai-Yoon SUL, Jinchun WANG, Mimi HEALY
-
Publication number: 20200216842Abstract: Disclosed herein are protein translation switches and conditional gene expression systems that are compatible with retroviral and lentiviral gene delivery. The linking of a protein translation switch to a 3? gene of interest suppresses translation of the gene of interest, and the alteration of the protein translation switch by DNA recombinase-mediated DNA recombination relieves the suppressed translation of the 3? gene of interest. Also disclosed herein are methods of mimicking clinical pharmacology in a pre-clinical setting.Type: ApplicationFiled: October 11, 2018Publication date: July 9, 2020Applicant: Massachusetts Institute of TechnologyInventor: Patrick J. Stern
-
Publication number: 20200216843Abstract: CRISPR/RNA-guided nuclease-related compositions and methods for treatment of A1AT deficiency and associated conditions are disclosed.Type: ApplicationFiled: March 24, 2017Publication date: July 9, 2020Inventors: Shen SHEN, Penrose O'DONNELL, Minerva SANCHEZ
-
Publication number: 20200216844Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.Type: ApplicationFiled: December 14, 2018Publication date: July 9, 2020Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
-
Publication number: 20200216845Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of RelA in a target cell. The oligonucleotides are complementary to mammalian RELA pre-m RNA intron sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.Type: ApplicationFiled: January 10, 2018Publication date: July 9, 2020Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT
-
Publication number: 20200216846Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.Type: ApplicationFiled: August 9, 2019Publication date: July 9, 2020Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and ScienceInventors: Frank Rigo, Michelle L. Hastings
-
Publication number: 20200216847Abstract: The subject invention provides methods of treating neurological disease or disorder, such as brain injuries, such as stroke, traumatic brain injury (TBI), or other ischemic events that cause brain injury by inhibiting or down-regulating Let-7i activity or function. The disclosed methods may have the potential to extend the “window of opportunity” for treatment of such injuries and enhance the effectiveness of existing therapeutics.Type: ApplicationFiled: August 13, 2018Publication date: July 9, 2020Inventors: MEHARVAN SINGH, CHANG SU, TRINH NGUYEN
-
Publication number: 20200216848Abstract: Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.Type: ApplicationFiled: September 21, 2018Publication date: July 9, 2020Inventors: Catherine R. O'RIORDAN, Adam PALERMO, Brenda RICHARDS, Lisa M. STANEK
-
Publication number: 20200216849Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.Type: ApplicationFiled: August 15, 2019Publication date: July 9, 2020Inventors: Carl Erickson, Christopher P. Rusconi, Kevin G. McLure, Matthew Levy, Arijit Bhowmick
-
Publication number: 20200216850Abstract: MicroRNAs embedded within an intron, which are called ‘mirtrons,’ can be used as a platform for expressing one or more shRNA or miRNA mimics in a lentiviral vector. The inventors developed a strategy to improve lentiviral titering by reducing the production of shRNA/miRNA from the vector during packaging through the introduction of splice-inhibiting antisense oligonucleotides during vector packaging, which inhibit the splicing of the mirtron and subsequent processing of the shRNAs/miRNAs. In an aspect is provided a kit comprising an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system. In an aspect is provided a method for producing a lentivirus. The method comprises the step of transfecting a cell with an oligonucleotide comprising a mirtron splice site binding sequence and a lentiviral packaging system; thereby producing the lentivirus.Type: ApplicationFiled: September 21, 2018Publication date: July 9, 2020Inventors: John C. Burnett, Elizabeth Epps, John J. Rossi
-
Publication number: 20200216851Abstract: Disclosed are a recombinant poly(ethylene terephthalate) hydrolase (PETase) expression vector, a recombinant mono(2-hydroxyethyl)terephthalate hydrolase (MHETase) expression vector, a strain for producing each of the recombinant PETase and MHETase containing each of the vectors, and a method for degrading a plastics using each of the recombinant PETase and MHETase expressed therefrom. When the recombinant hydrolases, that is, PETase and MHETase are used together, high enzymatic activity may be sustained for a long time to completely degrade the PET.Type: ApplicationFiled: December 2, 2019Publication date: July 9, 2020Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventor: Kyung Jin KIM
-
Publication number: 20200216852Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycm.Type: ApplicationFiled: December 19, 2019Publication date: July 9, 2020Inventors: Claus LATTEMANN, Mark BROENSTRUP, Stefan WERNER, Rolf MÜLLER, Kirsten HARMROLS
-
Publication number: 20200216853Abstract: The invention relates to a plant genetic engineering field, and more particularly to a method for creating directed gene mutated non-transgenic plants. The method including performing a transgenic method onto directed gene mutated plants by introducing exogenous nucleic acid molecules; wherein the transgenic method includes introducing constructs into the directed gene mutated plants, each of the constructs contains a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule serves as a gene editing element, and the second nucleic acid molecule serves as a lethal or stop development element, and can be used in a plant gene editing system such as CRISPR/CAS9. It can actively and automatically eliminate plant transgenic fragments, leaving enough time for gene editing elements to perform directed gene editing before removing transgenic fragments, providing a simple and effective method for gene editing without transgenic plants.Type: ApplicationFiled: January 19, 2020Publication date: July 9, 2020Inventor: YUBING HE
-
Publication number: 20200216854Abstract: Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants with increased tolerance to abiotic stress (e.g., high or low temperature, drought, flood).Type: ApplicationFiled: February 18, 2020Publication date: July 9, 2020Inventors: Cory Christensen, Nestor Apuya, Kenneth A. Feldmann
-
Publication number: 20200216855Abstract: The present invention provide the use of Nicotiana benthamiana (N. benthamiana) HIR3s gene and/or Oryza sativa HIR3 gene in producing plants with resistance to virus and the method for making the plants thereof, the method involve: constructing NbHIR3.1, NbHIR3.2 or OsHIR3 into plant binary expression vector pCV1300 respectively, and introduced into Agrobacterium by electric shock, then transgenic plants overexpressing either NbHIR3.1 or NbHIR3.2 gene or tobacco or rice overexpressing HIR3 were produced by infection with Agrobacterium; the nucleotide sequences of NbHIR3.1, NbHIR3.2 and OsHIR3 are shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively.Type: ApplicationFiled: July 26, 2019Publication date: July 9, 2020Inventors: Fei YAN, Saisai LI, Yuwen LU, Jinping ZHAO, Jiejun PENG, Hongying ZHENG, Lin LIN, Ye CHENG, Jianping CHEN
-
Publication number: 20200216856Abstract: Disclosed is a dsRNA construct used to silencing specific eukaryotic translation initiation factor in plants to produce a plant resistant to viruses such as Potyviruses, Luteoviruses, and Furoviruses. More specifically, the plant would be resistant to viruses such as Wheat streak mosaic virus, Triticum mosaic virus, Soil bourne mosaic virus, or Barley yellow dwarf virus. Also disclosed are non-transgenic wheat plants having the genes for eIF(iso)4E-2 or eIF4G silenced.Type: ApplicationFiled: March 19, 2020Publication date: July 9, 2020Inventors: John P. Fellers, Harold N. Trick, Luisa Cruz, Jessica Rupp
-
Publication number: 20200216857Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN2 whether ex vivo or in vivo. For example, the present disclosure provides materials and methods for treating a patient with Spinocerebellar ataxia type 1 (SCA2). Also provided are materials and methods for editing a ATXN2 gene in a cell by genome editing. The present disclosure also provides materials and methods for altering the contiguous genomic sequence of a ATXN2 gene in a cell. In addition, the present disclosure provides one or more gRNAs for editing a ATXN2 gene. Also provided are therapeutics comprising at least one or more gRNAs for editing a ATXN2 gene. In addition, the present disclosure provides therapeutics for treating patients with a ATXN2 related condition or disorder.Type: ApplicationFiled: February 21, 2018Publication date: July 9, 2020Applicant: CRISPR THERAPEUTICS AGInventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
-
Publication number: 20200216858Abstract: The present invention provides novel donor polynucleotides formed by linking the two ends of a genomic fragment containing a cleavable site by a polynucleotide carrying a positive selection marker gene and a negative selection marker gene. Use of the donor polynucleotide makes it possible to modify only a target gene with avoiding the possibility of introducing mutations to sequences, called “off-target”, which are other than the target sequence, by introducing cleavage in a homologous site of the donor polynucleotide without introducing cleavage in a target gene locus.Type: ApplicationFiled: July 19, 2018Publication date: July 9, 2020Applicant: I'ROM GROUP CO., LTD.Inventors: Kohji KUSANO, Takayuki KITOGO, Makoto INOUE, Tsugumine SHU, Toyotaka MORI
-
Publication number: 20200216859Abstract: An adenovirus comprising a sequence of formula (I) 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein By comprises a transgene cassette containing four transgenes, said genes encoding a FAP-BITE, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.Type: ApplicationFiled: August 28, 2018Publication date: July 9, 2020Inventors: Brian CHAMPION, Alice Claire, Noel BROMLEY
-
Publication number: 20200216860Abstract: The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichment RNA, or a sequence of a functional fragment or derivative thereof, wherein the enrichment RNA, or functional fragment or derivative thereof, is capable of enhancing inclusion of the gene-editing molecule mRNA, or functional fragment or derivative thereof, into a retroviral particle. The invention provides a method of producing the retroviral particles of the invention, the method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of retroviral particles.Type: ApplicationFiled: September 5, 2018Publication date: July 9, 2020Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Christos KYRATSOUS, Andrew J. MURPHY, Cheng WANG
-
Publication number: 20200216861Abstract: New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dosgs or human beings.Type: ApplicationFiled: February 27, 2020Publication date: July 9, 2020Applicant: Universitat Autònoma de BarcelonaInventors: Fàtima Bosch Tubert, Eduard Ayuso López, Callejas Castiñeiras David
-
Publication number: 20200216862Abstract: Methods, systems, processes, and apparatuses are provided for delivery across cell membranes. In one aspect, an apparatus includes a substrate including a mixing channel, a process chamber, and a dilution channel to perform delivery of the payload to across the cell membranes. In another aspect, a system includes reservoirs for a cell suspension, a delivery solution, and a stop solution connected to a pump. The system further includes an agitator, a heater, a temperature controller, and a controller to operate the system. In yet another aspect, cells in suspension are mixed with a delivery solution in a microfluidic mixing chip. The delivery solution includes a permeabilization agent to cause permeabilization of the cells, allowing delivery of a payload from the delivery solution to the cells across the cell membranes.Type: ApplicationFiled: July 18, 2018Publication date: July 9, 2020Inventor: Michael Maguire
-
Publication number: 20200216863Abstract: The present invention provides for a method to produce a biofuel and/or chemical compound from a biomass, the method comprising: (a) introducing a biomass and a deep eutectic solvent (DES), or mixture thereof, into a vessel to form a one-pot composition, wherein the DES, or mixture thereof, solubilizes the biomass; (b) introducing an enzyme and/or a microbe to the one-pot composition such that the enzyme and/or microbe produce a biofuel and/or chemical compound from the solubilized biomass; and, (c) optionally the biofuel and/or chemical compound is separated from the one-pot composition.Type: ApplicationFiled: January 8, 2020Publication date: July 9, 2020Applicants: National Technology & Engineering Solutions of Sandia, LLC, The Regents of the University of CaliforniaInventors: Feng Xu, Blake A. Simmons, Seema Singh
-
Publication number: 20200216864Abstract: The present disclosure provides methods for utilizing genetically modified microbes to co-produce 3-hydroxypropionic acid (3-HP) and acetyl-CoA, and derivatives thereof from malonate semialdehyde as a common single intermediate. The disclosure further provides modified microbe that co-produce the 3-HP and acetyl-CoA derivatives from malonate semialdehyde.Type: ApplicationFiled: December 18, 2019Publication date: July 9, 2020Inventors: Beatriz Leite MAGALHAES, Paulo Moises Raduan ALEXANDRINO, Felipe GALZERANI
-
Publication number: 20200216865Abstract: Certain embodiments provide a method for preparing a biochemical product (e.g., phenol, catechol, or muconic acid, or a salt thereof). For example, such methods include contacting a recombinant host having two or more recombinant pathways with a fermentable carbon source and growing the recombinant cell for a time sufficient to synthesize the product. In certain embodiments, each recombinant pathway: 1) is capable of producing the same final biochemical product; 2) comprises at least one gene encoding a polypeptide; 3) is derived from a different endogenous metabolite as its immediate precursor; and 4) converges to the same final product or the same intermediate metabolite.Type: ApplicationFiled: July 16, 2018Publication date: July 9, 2020Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: David NIELSEN, Brian THOMPSON
-
Publication number: 20200216866Abstract: Provided is a method of producing a mixture of pure feedstock-based native polyphenols from a feedstock. Contaminant polyphenols are first removed from an enzyme solution for converting feedstock to a product to produce a polyphenol reduced enzyme solution. The polyphenol reduced enzyme solution is combined with the feedstock and the feedstock is converted to a product and by-product. Heretofore, there has been no process available to reduce or remove the contaminant phenols introduced to the feedstock by commercial enzyme solutions. This method allows for the removal of contaminant phenols prior to introduction to the processing stream and subsequent harvesting of pure feedstock 6 based native polyphenols. The pure feedstock-based polyphenols are removed from the product or by-product to produce a pure mixture of feedstock-based polyphenols.Type: ApplicationFiled: July 26, 2018Publication date: July 9, 2020Inventor: Vincent Yacyshyn
-
Publication number: 20200216867Abstract: The invention provides a method of producing L-tryptophan, the method comprising culturing a L-tryptophan producing microorganism belonging to the Enterobacteriaceae family in a fermentation medium; wherein the L-tryptophan producing microorganism has been modified by enhancing the expression level of the mdfA gene or by enhancing the expression level of an mdfA allele.Type: ApplicationFiled: January 5, 2020Publication date: July 9, 2020Inventors: Mechthild Rieping, Silke Jerrentrup, Nicole Dusch
-
Publication number: 20200216868Abstract: A two-step method for activating a cellulosic feedstock is described. The feedstock is subjected to a first high temperature activation step at a temperature greater than 190° C. and a second activation step at a lower temperature under alkali conditions. Also described are methods and compositions for the enzymatic hydrolysis of activated cellulose using one or more cellulase enzymes, a surfactant and polyaspartic acid. Also described are products of the methods.Type: ApplicationFiled: March 20, 2020Publication date: July 9, 2020Applicant: Comet Biorefining Inc.Inventors: Andrew Richard, Dennis D'Agostino
-
Publication number: 20200216869Abstract: A method produces xylo-oligosaccharides from a biomass containing xylan and cellulose, which method is convenient and has a high yield of xylo-oligosaccharides because of inhibition of degradation of xylo-oligosaccharides into xylose. In the method of producing xylo-oligosaccharides, a biomass containing xylan and cellulose is hydrolyzed with a cellulase composition having at least activities of xylanase, cellobiohydrolase and ?-glucosidase and substantially free of ?-xylosidase activity during hydrolysis.Type: ApplicationFiled: March 30, 2017Publication date: July 9, 2020Inventors: Takuya Kasahara, Chiaki Yamada, Hiroyuki Kurihara, Katsushige Yamada
-
Publication number: 20200216870Abstract: The invention relates to a method and device for amplifying non-purified nucleic acid, where the method comprises the following steps: Providing a reaction device in which an amplification reaction reagent is placed; Sampling with a sampler: the sampler includes a sealing block and a sample needle connected with the sealing block. The end of the sample needle is provided with a hydrophilic surface, which contacts the non-purified nucleic acid sample for sampling; the hydrophilic surface is inserted into the amplification reaction reagent, and the reaction device is sealed by the sealing block; The temperature of the reaction device is controlled by the temperature control instrument to carry out the amplification reaction. The device of the invention is used for realizing the method. The invention can save the process of sample preparation and purification, directly amplify the non-purified sample, reduce the operation difficulty, save the time and reduce the cost.Type: ApplicationFiled: September 14, 2018Publication date: July 9, 2020Inventors: Xing SU, Kaiyuan WU
-
Publication number: 20200216871Abstract: Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.Type: ApplicationFiled: January 9, 2020Publication date: July 9, 2020Inventors: Brian AGNEW, Kyle GEE, Tamara NYBERG
-
Publication number: 20200216872Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein, wherein an f-met group on the 5?-terminus is enzymatically removed. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.Type: ApplicationFiled: March 16, 2020Publication date: July 9, 2020Applicant: Fina BioSolutions, LLCInventors: Natalia Oganesyan, Andrew Lees
-
Publication number: 20200216873Abstract: An immobilized enzymatic reactor can include a wall defining a chamber having an inlet and an outlet; a solid stationary phase covalently linked to an enzyme and disposed within the chamber; and a pressure modulator in fluid communication with the chamber and adapted to support continuous flow of a liquid sample comprising a polymer analyte through the inlet, over the solid stationary phase, and out of the outlet under a pressure between about 2,500 and 35,000 psi. In one example, the solid stationary phase includes inorganic/organic hybrid particles in an ultra performance liquid chromatography system, the enzyme is a protease, and the polymer analyte is a polypeptide. The immobilized enzymatic reactor can prepare an analyte for applications such as for hydrogen deuterium exchange mass spectrometry.Type: ApplicationFiled: December 16, 2019Publication date: July 9, 2020Applicant: Waters Technologies CorporationInventors: JOOMI AHN, MOON CHUL JUNG, KEVIN D. WYNDHAM
-
Publication number: 20200216874Abstract: Provided are a PCR primer pair and an application thereof. The PCR primer pair comprises a first primer and a second primer, wherein the first primer comprises a first specific sequence, a first random sequence, and a first universal sequence, the first specific sequence is located at the 3? end of the first primer, the first random sequence is located at the 5? end of the first primer, and the first universal sequence is located between the first specific sequence and the first random sequence; the second primer comprises a second specific sequence, a second random sequence, and a second universal sequence, the second specific sequence is located at the 3? end of the second primer, the second random sequence is located at the 5? end of the second primer, and the second universal sequence is located between the second specific sequence and the second random sequence, wherein the first random sequence and the second random sequence are inversely complementary.Type: ApplicationFiled: June 20, 2017Publication date: July 9, 2020Inventors: Lin Yang, Haojun Jiang, Peng Zeng, Xuehan Zhuang, Ya Gao, Yanyan Zhang, Hui Jiang, Jing Guo, Fang Chen, Xun Xu
-
Publication number: 20200216875Abstract: The invention relates to a nucleic acid determination method, which is implemented by the sealed reaction vessel including a tubular chamber and a channel connecting the tubular chamber; the first tubular chamber is provided with the sample and the first set reaction reagent, and the nth tubular chamber is provided with the nth set reaction reagent; the method comprises the following steps: sealing the reaction vessel, conducting the first set of reactions in the first tubular chamber, and the products in the first tubular chamber are transported to the latter tubular chamber through a channel; after the product of the former tubular chamber is transported to the nth tubular chamber, the nth set reaction is carried out in the nth tubular chamber. The nucleic acid determination method provided by the invention can ensure the sealed closed system and convenient and simple operation.Type: ApplicationFiled: September 14, 2018Publication date: July 9, 2020Inventors: Xing SU, Kaiyuan WU
-
Publication number: 20200216876Abstract: A disposable assay platform for detecting a target nucleic acid comprising multiple chambers and a method for operating the assay platform. Solutions containing the target nucleic acid move from one chamber to the next chamber by opening a vent pocket. The resulting pressure change enables the solution to flow to the next chamber. The platform comprises an electronic layer and one or more fluid layers bonded together. All heating operations can be performed by using resistive heating elements in the platform. All cooling operations are preferably passive. The platform is preferably operated when in a vertical orientation and can be docked to an external docking station that controls the operation of the platform.Type: ApplicationFiled: November 8, 2019Publication date: July 9, 2020Inventors: Marc DEJOHN, Robert B. CARY, Nathan J. COBB
-
Publication number: 20200216877Abstract: The disclosure provides for methods, compositions, and kits for normalizing nucleic acid libraries, for example sequencing libraries.Type: ApplicationFiled: February 4, 2020Publication date: July 9, 2020Inventors: Craig Betts, Glenn Fu
-
Publication number: 20200216878Abstract: The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5? terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule.Type: ApplicationFiled: March 4, 2020Publication date: July 9, 2020Applicant: CureVac Real Estate GmbHInventor: Aniela WOCHNER
-
Publication number: 20200216879Abstract: This invention provides a DNA probe that is applicable to a DNA library prepared in a simple manner with excellent reproducibility. Such DNA probe is produced by a method comprising steps of performing a nucleic acid amplification reaction in a reaction solution containing genomic DNA and a random primer at a high concentration, so as to obtain a DNA fragments with the use of the genomic DNA as a template; determining the nucleotide sequence of the resulting DNA fragments; and, on the basis of the nucleotide sequence of the DNA fragments obtained in the step above, designing a DNA probe used for detecting a DNA fragment.Type: ApplicationFiled: June 26, 2017Publication date: July 9, 2020Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Hiroyuki ENOKI, Yoshie TAKEUCHI, Minoru INAMORI
-
Publication number: 20200216880Abstract: Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencingType: ApplicationFiled: September 5, 2019Publication date: July 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Guy GEORGES, Stefan KLOSTERMANN, Alain TISSOT, Francesca ROS, Alexander BUJOTZEK, Clemens WRZODEK, Frederic SCHULTZ
-
Publication number: 20200216881Abstract: The present invention concerns compositions, kits and methods for genetic variation detection and classification. These methods combine the specificity of a ligation reaction with the single-molecule sensitivity of nanopore biosensors. This invention can achieve clinical detection of many diseases, including bacterial infections and cancer entities, by identification of specific genetic alterations.Type: ApplicationFiled: June 14, 2018Publication date: July 9, 2020Inventors: Amit MELLER, Michelle PATKIN, Tal GILBOA, Yana BEN ZVI ROZEVSKY
-
Publication number: 20200216882Abstract: The present application relates to new coumarin compounds and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.Type: ApplicationFiled: January 9, 2020Publication date: July 9, 2020Inventor: Nikolai Nikolaevich Romanov
-
Publication number: 20200216883Abstract: A method of sequencing a nucleic acid comprising the steps of (1) generating a stream of single nucleoside triphosphates; (2) producing at least one substantially double-stranded primary oligonucleotide used probe by reacting with a corresponding primary probe comprising (a) a first single-stranded oligonucleotide including a restriction endonuclease nicking-site, a single nucleotide capture site, and oligonucleotide flanking regions.Type: ApplicationFiled: September 6, 2017Publication date: July 9, 2020Applicant: Base4 Innovation LimitedInventors: Barnaby BALMFORTH, Cameron Alexander FRAYLING
-
Publication number: 20200216884Abstract: A portable diagnostic device has a lysate stage with a port for receiving a sample and containing magnetic beads with a probe, and an outlet port. A series of assay stages are linked with the lysate vessel, each with a reservoir linked by channels. The final stage has a sensor for detecting beads attached to analyte molecules which have been conveyed according to attachment to probes on beads. Larger transport beads cause reporter beads which are tethered by target NA and probes to be transported to the final sensor stage, where they are released and detected when the transport beads have been removed.Type: ApplicationFiled: September 6, 2018Publication date: July 9, 2020Applicant: ALTRATECH LIMITEDInventors: Brian O'FARRELL, Cian Desmond O'SULLIVAN, John O'DRISCOLL, Timothy CUMMINS, Paul FREE, Moira MCCARTHY, John WALSHE
-
Publication number: 20200216885Abstract: Described herein are products and processes for nucleic acid quantification, which are in part useful for detecting and determining the nucleotide sequence of rare nucleic acids (i.e., low copy number nucleic acids) in a sample. Such products and processes are useful for reducing the dynamic range among different nucleic acid species.Type: ApplicationFiled: December 4, 2019Publication date: July 9, 2020Applicant: Sequenom, Inc.Inventor: Charles R. Cantor
-
Publication number: 20200216886Abstract: The invention relates to control compositions for a quantitative polymerase chain reaction. More particularly, the invention relates to control compositions for a quantitative polymerase chain reaction having at least one barcode sequence fragment and at least a first and a second primer binding site fragment, and to methods of their use.Type: ApplicationFiled: December 13, 2019Publication date: July 9, 2020Inventor: Rachel R. SPURBECK
-
Publication number: 20200216887Abstract: A method is provided for preparing nanopore sequencing complexes in membranes for sequencing of polymers, e.g., polynucleotides and polypeptides. The nanopore sequencing complex is formed by the sequential linking of an enzyme to a nanopore that is inserted in a membrane, and of a polymer to the enzyme. Alternatively, the nanopore sequencing complex is formed by linking a preformed enzyme-polymer complex to a nanopore that is inserted in a membrane. The enzyme polymer complex is interchangeable.Type: ApplicationFiled: January 20, 2017Publication date: July 9, 2020Applicant: Genia Technologies, Inc.Inventors: Timothy Kellogg Craig, Christos Tzitzilonis, Alexander H. Yang, Liv E. Jensen, Marshall Porter, Charlotte Yang, Corissa Harris, Matt Dipetro
-
Publication number: 20200216888Abstract: The present invention relates to a method for increasing the efficiency of read data analysis by removing primer sequence information present in a read obtained through next-generation sequencing (NGS) and, more specifically, to a method for matching information of a read and a designed primer to various reference values in several steps so as to determine primer sequence information within a read, and then precisely removing only a primer sequence so as to increase the efficiency of read data analysis. The method for increasing the efficiency of read data analysis in a primer removal-based NGS, according to the present invention, has a rapid data analysis speed and can precisely remove only a primer sequence, thereby being useful for increasing the efficiency and accuracy of read data analysis.Type: ApplicationFiled: August 9, 2018Publication date: July 9, 2020Inventors: Chang Seon LEE, Chang Bum HONG, Ensel OH, Kwang Joong KIM